.png)
ზუსტად ერთი წლის წინ ვთქვი, რომ საქართველოში ჩინური ვაქცინების გამოყენება უნდა შეჩერდეს-მეთქი, ვინაიდან უკვე არსებობს არაერთი კვლევა, რომ ეს ვაქცინები დაბალეფექტურია, განსაკუთრებით, კოვიდის ახალი შტამების წინააღმდეგ (დელტა/ომიკრონი).
სამწუხაროდ, დღესაც ამ ვაქცინებს იყენებენ საქართველოში… ვადა არ გასდის? თუ უვადოა? წყაროები მითითებულია… ჯანმრთელობას გისურვებთ …
#drpkhakadze @drpkhakadze #გიორგიფხაკაძე
Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial. Nawal AlKaabi*, Yun Kai Yang*, Jing Zhang*#, Ke Xu*, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang‡, Mengjie Yang, Islam ElTantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang†, Xiao Ming Yang†, Guizhen Wu†, Qi Ming Li†
Declaration of interests JingZ#, YL, YK, JGS, SS, SSY, NL, FJS, QML are employees of the National Vaccine and Serum Institute (NVSI). YKY, TY, ML, XZ, CQ, DYL, ZNW, JLY, LQ, YTZ, XMY are employees of the China National Biotec Group Company Limited. XJG, XYM, are employees of Lanzhou Institute of Biological Products Company Limited. HW, JinZ are employees of Beijing Institute of Biological Products Company Limited. ZJ is an employee of Beijing KeyTech Statistical Consulting Co.,Ltd. HMM is an employee of Union 71, United Arab Emirates. WZ, SM, IE, PX are employees of G42 Healthcare, IROS (Insights Research Organization & Solutions), United Arab Emirates. JingZ#, YL, JGS, SS, NL, QML are listed as inventors of the patent applications for the trimeric RBD-based vaccines (Application numbers: 202110348881.6, 202110464788.1 and 202110676901.2) and a patent (Application number: 202110676901.2) has been authorized.
Findings: A total of 1800 individuals who have received two doses of BBIBP-CorV were enrolled, of which 899 participants received a heterologous boost of NVSI-06-07 and 901 received a homologous boost for comparison The heterologous BBIBP-CorV/NVSI-06-07 prime-boosting vaccination may be valuable in preventing the pandemic of Omicron. The optimal booster strategy was the heterologous boost with NVSI-06-07 over 6 months after a priming with two doses of BBIBP-CorV.
https://www.medrxiv.org/content/10.1101/2021.12.29.21268499v1.full.pdf (35 pages)
BEIJING, Jan 7 (Reuters) - A protein-based COVID-19 vaccine made by Sinopharm, when given as a booster after two doses of an earlier shot from the Chinese firm, elicited a stronger antibody response against the Omicron variant than a third dose of the original, a study showed.
An earlier study showed a BBIBP-CorV booster had weaker neutralisation against Omicron than against an older coronavirus strain from the central Chinese city of Wuhan
inopharm's NVSI-06-07 protein-based vaccine, approved for emergency use as a booster in the United Arab Emirates in December, adopts a different technology than the BBIBP-CorV shot that contains an inactivated form of the coronavirus.
Among 192 healthy adults vaccinated with two BBIBP-CorV doses for six months or longer, the neutralising antibody level against Omicron in those later given a NVSI-06-07 booster was "significantly higher" than that in those who received a BBIBP-CorV third dose, researchers said in a paper.
The authors of the study, which was published on Tuesday and had not been peer reviewed, included researchers from Sinopharm’s units and Sheikh Khalifa Medical City in Abu Dhabi. They cautioned that it remained unclear for how long Sinopharm’s NVSI-06-07 booster’s effect would last. Sinopharm’s NVSI-06-07 protein-based vaccine adopts a different technology than the BBIBP-CorV shot that contains an inactivated form of the coronavirus.
Among 192 healthy adults vaccinated with two BBIBP-CorV doses for six months or longer, the neutralizing antibody level against Omicron in those later given a NVSI-06-07 booster was “significantly higher” than that in those who received a BBIBP-CorV third dose, researchers said in a paper.
BEIJING, Dec 20 (Reuters) - A COVID-19 booster shot produced by China's Sinopharm had "significantly lower" neutralising activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine's efficacy against Omicron remained unclear.
The neutralising antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction, compared with its activity against a Wuhan strain, according to the paper published on Saturday.
BEIJING, Dec 20 (Reuters) - A COVID-19 booster shot produced by China's Sinopharm had "significantly lower" neutralising activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine's efficacy against Omicron remained unclear.
29 March, 2021. -A new factory in Abu Dhabi will start manufacturing a COVID-19 vaccine from Chinese pharmaceutical giant Sinopharm later this year under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42 (G42).
---
Professor Giorgi Pkhakadze, MD, MPH, PhD
ავტორი: გიორგი ფხაკაძე
